ZP4207

DRUG4 trials

Sponsors

Zealand Pharma, University Hospital, Gentofte, Copenhagen

Conditions

Hyperinsulinemic HypoglycemiaHypoglycemiaPostprandial Hypoglycemia

Phase 1

Single Ascending Doses of ZP4207 Administered in HV and in T1D to Evaluate Safety, Tolerability PKs and PDs of ZP4207 Compared to a Comparator

CompletedNCT02367053

Zealand PharmaHypoglycemia

Start: 2014-12-31End: 2015-04-30Updated: 2016-01-22

Multiple Ascending Doses of ZP4207 Administered to HV to Evaluate the Safety, Tolerability, PKs and PDs of ZP4207

CompletedNCT02390141

Zealand PharmaHypoglycemia

Start: 2015-04-30End: 2015-08-31Updated: 2015-11-11

Phase 2

Single Doses of ZP4207 Adm. sc to Hypoglycemic TD1 pt. to Describe the PK and PD of ZP4207 as Comp. to Marketed Glucagon

CompletedNCT02660008

Zealand PharmaHypoglycemia

Start: 2016-01-31End: 2016-06-30Updated: 2016-06-15

Dasiglucagon in the Treatment of Postprandial Hypoglycaemia After Roux-en-Y Gastric Bypass

CompletedNCT03984370

University Hospital, Gentofte, CopenhagenHyperinsulinemic Hypoglycemia, Postprandial Hypoglycemia

Start: 2019-09-18End: 2020-02-26Updated: 2020-03-31